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Background. Retention in human immunodeficiency virus (HIV) care is dynamic, with patients frequently transitioning in and 
out of care. Analytical approaches (eg, survival analyses) commonly used to assess HIV care cascade outcomes fail to capture such 
transitions and therefore incompletely represent care outcomes over time.
Methods. We analyzed antiretroviral therapy (ART)-eligible adults newly linking to care at 64 clinics in Zambia between 1 April 
2014 and 31 July 2015. We used electronic medical record data and supplemented these with updated care outcomes ascertained 
by tracing a multistage random sample of patients lost to follow-up (LTFU, >90 days late for last appointment). We performed 
multistate analyses, incorporating weights from sampling, to estimate the prevalence of 9 care states over time since linkage with 
respect to ART initiation, retention in care, transfers, and mortality.
Results. In sum, 23 227 patients (58% female; median age 34 years [interquartile range 28–41]) were ART-eligible at enrollment. 
At 1 year, 75.2% had initiated ART and were in care: 61.8% were continuously retained, 6.1% had reengaged after LTFU, and 7.3% 
had transferred. Also, 10.1% were LTFU within 7 days of enrollment, and 15.2% were LTFU at 1 year (6.7% prior to ART). One year 
after LTFU, 51.6% of those LTFU prior to ART remained out of care compared to 30.2% of those LTFU after initiating ART. Overall, 
6.9% of patients had died by 1 year with 3.0% dying prior to ART.
Conclusion. Multistate analyses provide more complete assessments of longitudinal HIV cascade outcomes and reveal treat-
ment gaps at distinct timepoints in care that will still need to be addressed even with universal treatment.
Keywords.  multistate analysis; HIV care cascade; retention in care; mortality; Zambia.
Despite rapid expansion of antiretroviral therapy (ART) cov-
erage in sub-Saharan Africa over the past decade, human im-
munodeficiency virus (HIV) treatment outcomes such as 
viral suppression and mortality still remain suboptimal [1]. 
Successful treatment requires a series of steps—which include 
linkage to HIV care, ART initiation, and retention—but sig-
nificant care gaps exist at each step of this HIV care cascade. 
Although previous studies have highlighted that patients fre-
quently transition back and forth between care cascade steps 
over time [2–8], current approaches to understanding these 
treatment gaps still frequently approach the cascade as a linear 
sequence of events [2–10]. These approaches either represent 
the care cascade as a series of cross-sectional estimates or use 
longitudinal methods to examine only 1 cascade step at a time. 
By overlooking patient transitions into and out of different care 
states over time (ie, retained vs not retained, on ART vs not on 
ART), these assessments may provide incomplete representa-
tions of the actual longitudinal experience of patients receiving 
HIV care [2–10].
Multistate analytic approaches can account for patient tran-
sitions in between different care states over time and may better 
characterize patients’ care and treatment experience [11–13]. By 
highlighting the combined dynamics of multiple cascade steps, 
these approaches provide more complete and nuanced repre-
sentations of longitudinal patient outcomes and can more pre-
cisely characterize the remaining care gaps. For example, in the 
current era of universal treatment, the question remains as to 
whether rapidly initiating ART actually improves downstream 
outcomes. Traditional approaches to the care continuum typi-
cally will examine effects on either ART initiation or retention in 
isolation, but multistate approaches can extend these insights by 
also identifying whether early loss to follow-up (LTFU) simply 
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shifts from pre- to post-ART or whether failures to initiate ART 
are driven by patients becoming LTFU or provider-level delays. 
This type of comprehensive assessment of patient cares states 
over time can thus better characterize the persistent treatment 
gaps and, ultimately, inform how to best target and implement 
interventions to improve the HIV care cascade [5–10].
In this analysis, we use multistate analytic techniques to ex-
amine longitudinal care experience among patients eligible for 
ART newly linking to HIV care in Zambia in a way that ac-
counts for several key transitions along the HIV care cascade, 
including ART initiation, transitions into and out of retention 
in care, transfers to new clinics, and death.
METHODS
Patient Population and Setting
We analyzed a cohort of ART-naiive adults (>18 years old) with 
HIV who newly enrolled in care between 1 April 2014 and 31 
July 2015 and who were eligible for ART according to Zambian 
national treatment guidelines at the time of enrollment (ie, a 
CD4 count <500 cells/μL, active tuberculosis, World Health 
Organization [WHO] clinical stage 3 or 4 disease, or preg-
nancy or breastfeeding [14]). Patients were from 64 Zambian 
Ministry of Health clinics that received technical support from 
the Centre for Infectious Disease Research in Zambia (CIDRZ), 
a nongovernmental organization operating across 4 of the 10 
provinces in Zambia.
Measurements
Sociodemographic, clinical, facility-level, and visit history 
measurements were obtained from the national electronic med-
ical record (EMR) system used in routine HIV care in Zambia. 
To populate the EMR, providers first complete standardized 
paper clinical forms during routine patient encounters, and 
then data clerks enter this information into the electronic data-
base. Additionally, we undertook a multistage sampling-based 
approach in order to obtain accurate population-representative 
estimates of retention and mortality (S1 appendix) [15–17]. We 
first took a stratified random sample of 32 of the total 64 facil-
ities, and then, at selected facilities, we enumerated a random 
sample of patients who were LTFU as of 31 July 2015 (defined 
as being at least 90 days late for the last scheduled visit or more 
than 180 days without any visit based on guidelines at the time 
[18]). Selected patients were then traced using a combination of 
chart review, phone calls, and in-person visits within the com-
munity, and we used structured questionnaires to record their 
current vital and care status and associated dates.
Analyses
We sought to describe the longitudinal experience of patients 
newly enrolling in HIV care in a manner that accounted for transi-
tions between ART states (eg, initiated on ART or not) and reten-
tion states (eg, in care, LTFU, reengaged after LTFU, transferred) 
over time [11–13]. To do so, we used multistate analytic techniques 
to estimate the probability of a patient being in a particular care 
state at any given time point since enrollment. We first categor-
ized patients at each time point into 1 of 9 mutually exclusive and 
exhaustive states: (1) not initiated on ART and in care, (2) out of 
care prior to initiating ART, (3) transfer to another clinic prior to 
initiating ART, (4) death prior to initiating ART, (5) initiated on 
ART and consistently in care (ie, no LTFU after initiating ART), 
(6) out of care after initiating ART, (7) reengaged in care at the orig-
inal clinic after LTFU on ART, (8) transfer to another clinic after 
initiating ART, and (9) death after initiating ART (Figure 1). We 
then applied nonparametric multistate analytic techniques based 
Figure 1. State transitions framework for multistate analysis. At each time point, patients were categorized into 1 of 9 mutually exclusive and exhaustive states: (1) not 
initiated on ART and in care, (2) out of care prior to initiating on ART, (3) transfer to another clinic prior to initiating ART, (4) death prior to initiating ART, (5) initiated on ART 
and consistently in care (ie, no LTFU after initiating ART), (6) out of care after initiating ART, (7) reengaged in care at the original clinic after LTFU on ART, (8) transfer to an-
other clinic after initiating ART, and (9) death after initiating ART. This figure depicts all the possible transitions patients could make from each state. Abbreviations: ART, 
antiretroviral therapy; LTFU, lost to follow-up.
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on the Aalen-Johansen method that are designed to account for pa-
tient transitions into and out of multiple nonabsorbable states over 
time [11–13, 19]. Time zero was the enrollment date, and patients 
were censored at the time of transfer, death, or the end of the obser-
vation period (ie, 31 July 2015). In addition, we performed separate 
analyses to assess outcomes specifically among patients after ART 
initiation or LTFU from care; time zero for these analyses was the 
entry date into that particular state. Finally, we performed stratified 
analyses among patient subgroups, reporting the proportion of pa-
tients in each of 4 composite states at 1 year since enrollment: (1) in 
care and on ART (a composite of ART in care [state 5], reengaged 
on ART [state 7], and transferred on ART [state 8]), (2) LTFU, (3) 
transfer to a new clinic, and (4) died. All analyses incorporated 
sampling weights based on the inverse of the probability of having 
outcomes successfully ascertained from the multistage sampling; 
weights were recalibrated for subgroups in stratified analyses (S1 
appendix) [20]. We used bootstrapping (n = 1000 iterations) to ob-
tain 95% confidence intervals. Analyses were conducted using the 
mstate package in R [12, 13].
Finally, we also used Cox proportional-hazards models to 
identify baseline characteristics independently associated with 
LTFU, transfer, and death both prior to and after ART initiation. 
We used multiple imputation (n = 20) to address missingness in 
predictor variables [15, 16].
RESULTS
Patient Characteristics
During the study period, 23 227 people eligible for ART newly 
enrolled in HIV care at one of 64 clinics across 4 provinces in 
Zambia (Figure 2). Most were female (58.0%), with a median 
age of 34 years (interquartile range [IQR] 28–41) and median 
enrollment CD4 count of 268 cells/µL (IQR 134–430). We at-
tempted to trace 501 LTFU patients between September 2015 
and July 2016 and successfully ascertained updated vital and 
care status in 337 (67.3%). Sampled patients and those success-
fully traced were mostly similar in baseline characteristics, al-
though we were less successful in tracing younger patients and 
those from Lusaka province (Table 1).
Longitudinal Care Cascade Outcomes From Multistate Analyses
Among people eligible for ART at the time of enrollment, 71.9% 
had initiated ART by 3 months, and 87.6% had initiated ART by 
12 months. At 1 year, 75.2% of patients had initiated ART and 
were still in care: 61.8% had remained consistently retained at 
the original facility; 6.1% were reengaged after previously ex-
periencing LTFU; and 7.3% had transferred to another clinic. 
Only 1.3% of patients were in care but had not yet initiated ART. 
Also, 10.1% of patients dropped out of care within 7 days of en-
rollment, and 15.2% were out of care at 1 year, with 6.7% being 
out of care without ever initiating ART and the remaining 8.5% 
out of care after initiating ART. Overall, 6.9% of patients had 
died by 1 year with 3.0% dying prior to initiating ART and 3.9% 
dying after initiating ART (Figure 3, Table S1).
Among people who initiated ART, 86.2% overall were in care 
and on ART 1 year after initiating ART (68.3% continuously in 
care, 8.5% reengaged after LTFU, and 9.4% transferred), 8.8% 
of patients were LTFU, and 5.0% had died. Among the LTFU, 
reengagement substantially differed depending on whether 
Figure 2. Patient flowchart. In sum, 23 227 patients eligible for ART at the time of enrollment at 64 sites were included in this analysis. As of 1 July 2015, 5516 were con-
sidered LTFU, and we randomly selected 501 patients from 32 sites for active tracing. We ascertained updated vital status in 395 (78.8%) of the patients and updated care 
status in 241 of the 299 patients known to be alive (80.6%). Abbreviations: ART, antiretroviral therapy; LTFU, lost to follow-up.
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LTFU occurred prior to or after initiating ART. At 1 year after 
becoming LTFU prior to ART, only 31.7% of patients were in 
care and initiated on ART, whereas 51.6% remained LTFU, 5.8% 
transferred to another clinic, and 7.4% died. In contrast, among 
those who were LTFU after initiating ART, 66.9% were in care 
and on ART, 30.2% were still LTFU, 12.9% had transferred, and 
2.8% had died (Figure 4, Table S2).
In subgroup analyses, women >50  years old, patients at-
tending a hospital-based clinic, and patients not from Lusaka 
province were most likely to be in care and on ART at 1 year. 
In contrast, patients with higher enrollment CD4s, divorced 
or widowed patients, patients not attending a hospital-based 
clinic, and those from Lusaka province had a higher proportion 
of out of care at 1 year. The patients most likely to transfer to 
a new facility were men between the age of 25 and 50, women 
over 50, single patients, and those with more education. Finally, 
those most likely to die included older women, men irrespective 
of age, those with lower CD4 and higher WHO stage, single pa-
tients, and patients from Western province (Figure 5, Table S3).
Factors Associated With LTFU, Transfer, and Death Prior to and After ART 
Initiation
In multivariable regression, LTFU prior to ART was associated 
with a higher CD4 and being from Lusaka, whereas LTFU after 
Table 1. Baseline Patient Characteristics, N = 23 227
All Patients  







Sex, n (%)     
 Male 9764 (42.0%) 2418 (43.8%) 225 (44.9%) 158 (46.9%)
 Female 13 463 (58.0%) 3098 (56.2%) | 276 (55.1%) 179 (53.1%)
Enrollment age, n (%)     
 <25 y 2885 (12.4%) 840 (15.2%) 66 (13.2%) 36 (10.7%)
 25–35 y 9281 (40.0%) 2351 (42.6%) 198 (39.5%) 128 (38.0%)
 35–50 y 9006 (38.8%) 1907 (34.6%) 201 (40.1%) 144 (42.7%)
 >50 y 2055 (8.8%) 418 (7.6%) 36 (7.2%) 29 (8.6%)
Enrollment CD4 count (cells/μL), n (%)     
 <200 9234 (39.8%) 2248 (40.8%) 207 (41.3%) 146 (43.3%)
 200–350 6321 (27.2%) 1284 (23.3%) 100 (20.0%) 61 (18.1%)
 350–500 4557 (19.6%) 979 (17.7%) 93 (18.6%) 65 (19.3%)
 >500 1371 (5.9%) 468 (8.5%) 39 (7.8%) 24 (7.1%)
 Unknown 1744 (7.5%) 537 (9.7%) 62 (12.4%) 41 (12.2%)
Enrollment WHO stage, n (%)     
 I 9941 (42.8%) 2113 (38.3%) 189 (37.7%) 123 (36.5%)
 II 3977 (17.1%) 784 (14.2%) 78 (15.6%) 50 (14.8%)
 III 6107 (26.3%) 1784 (32.3%) 139 (27.7%) 95 (28.2%)
 IV 505 (2.2%) 172 (3.1%) 26 (5.2%) 16 (4.7%)
 Unknown 2697 (11.6%) 663 (12.0%) 69 (13.8%) 53 (15.7%)
Marital status, n (%)     
 Single 2527 (10.9%) 694 (12.6%) 70 (14.0%) 53 (15.7%)
 Married 11 965 (51.5%) 2798 (50.7%) 272 (54.3%) 190 (56.4%)
 Divorced 2901 (12.5%) 751 (13.6%) 54 (10.8%) 36 (10.7%)
 Widowed 1621 (7.0%) 331 (6.0%) 36 (7.2%) 24 (7.1%)
 Unknown 4213 (18.1%) 942 (17.1%) 69 (13.8%) 34 (10.1%)
Education, n (%)     
 None 1494 (6.4%) 345 (6.3%) 39 (7.8%) 23 (6.8%)
 Lower-mid basic 6926 (29.8%) 1579 (28.6%) 181 (36.1%) 132 (39.2%)
 Upper basic/secondary 9872 (42.5%) 2521 (45.7%) 202 (40.3%) 129 (38.3%)
 College/university 897 (3.9%) 183 (3.3%) 26 (5.2%) 22 (6.5%)
 Unknown 4038 (17.4%) 888 (16.1%) 53 (10.6%) 31 (9.2%)
Facility type, n (%)     
 Urban 14 259 (61.4%) 3927 (71.2%) 255 (50.9%) 160 (47.5%)
 Rural 1610 (6.9%) 420 (7.6%) 122 (24.4%) 100 (29.7%)
 Hospital 7358 (31.7%) 1169 (21.2%) 124 (24.8%) 77 (22.8%)
Province, n (%)     
 Lusaka 13 177 (56.7%) 3901 (70.7%) 265 (52.9%) 154 (45.7%)
 Eastern 4446 (19.1%) 586 (10.6%) 75 (15.0%) 55 (16.3%)
 Southern 2573 (11.1%) 448 (8.1%) 102 (20.4%) 77 (22.8%)
 Western 3031 (13.0%) 581 (10.5%) 59 (11.8%) 51 (15.1%)
Abbreviation: WHO, World Health Organization.
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ART was associated with younger age, being married, and not 
attending a hospital-based facility. Patients who were men, not 
married, and less sick (ie, higher CD4 count and lower WHO 
stage) were more likely to transfer prior to ART, whereas those 
who were men, older, single, and sicker (ie, lower CD4 count 
and higher WHO stage) were more likely to transfer after ART. 
Finally, lower CD4 count (but not higher WHO stage) was asso-
ciated with dying prior to ART, whereas older age, higher WHO 
stage (but not lower CD4 count), and being from a rural area (ie, 
not Lusaka) were more likely to die after initiating ART (Table 2).
DISCUSSION
Using multistate analytic methods, we characterized the longi-
tudinal experience of ART-eligible patients newly enrolling in 
HIV care accounting for the transitions between different care 
states that a patient may make over time. After 1 year, 75.2% 
of patients had initiated ART and were in care overall; 61.8% 
had remained consistently retained, 6.1% were reengaged after 
LTFU, and 7.3% had transferred to another clinic. In addition, 
10.1% of patients became LTFU within 7 days of enrollment, and 
15.2% of patients were out of care at 1 year with 6.7% out of care 
prior to even initiating ART. Overall, 6.9% of patients had died 
by 1 year with 3.0% dying prior to initiating ART. Among the 
LTFU, reengagement by 1 year substantially differed depending 
on whether LTFU occurred prior to (51.6% remained LTFU) 
or after initiating ART (30.2% remained LTFU). Overall, these 
findings provide a comprehensive depiction of the HIV care ex-
perience over time among patients eligible for ART at the time 
of enrollment and highlights the importance accounting for 
care transitions when examining longitudinal outcomes along 
the HIV care cascade.
Our study demonstrates that early disengagement from care 
has potential to limit the impact of current policies for universal 
treatment if not adequately addressed. Among people who were 
eligible for ART, failure to start ART was primarily concen-
trated in patients who became LTFU early on—a majority of 
whom did so after only 1 visit to the clinic—with very few pa-
tients who remained in care not being initiated on ART. It is 
unclear whether rapid ART initiation efforts will simply shift 
early LTFU from prior to ART initiation to post-ART initia-
tion in real-world settings, potentially limiting their impact on 
longer-term outcomes [21–29]. In our study, 43.5% of all mor-
tality occurred in patients prior to ART initiation, and 48.2% 
of these patients had at least a 30-day lapse in care prior to 
their death. Although it is unclear in whom ART would have 
altered these outcomes, the effects of rapid and universal ART 
initiation may be blunted if they do not occur in tandem with 
sustained retention after linkage. Thus, effective strategies for 
rapidly cultivating meaningful engagement beyond the initial 
visit are needed, and metrics for early treatment success should 
integrate both ART initiation and early retention to be most rel-
evant for the contemporary era [30, 31].
Figure 3. Longitudinal outcomes among people eligible for ART newly linking to care.This figure represents longitudinal outcomes among 23 227 people eligible for ART 
newly linking to care in Zambia based on results from the overall multistate analysis. The figure depicts the proportion of patients estimated to be in each care state at any 
given time point accounting for the transitions patients made between different care states over time. Abbreviations: ART, antiretroviral therapy; LTFU, lost to follow-up.
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Figure 4. Longitudinal outcomes among patients newly entering a specific care state. These figures represent longitudinal outcomes among the patients after newly en-
tering 3 specific care states. A, Outcomes after patients initiate ART. B, Outcomes after patients become LTFU prior to initiating ART. C, Outcomes after patients become LTFU 
after previously initiating ART. Abbreviations: ART, antiretroviral therapy; LTFU, lost to follow-up.
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Figure 5. Forest plot of results from multistate analyses stratified by patient subgroups. This figure depicts the proportion of patients in 1 of 4 composite care states at 
1 year after performing stratified multistate analysis. A, Proportion in each subgroup who are in care and on ART (a composite of ART in care [state 5], reengaged on ART 
[state 7], and transferred on ART [state 8]). B, Proportion of each subgroup who are LTFU (a composite of LTFU prior to ART [state 2] and LTFU after ART [state 6]). C, Proportion 
in each subgroup who transferred to a new clinic (a composite of transfer prior to ART [state 3] and transfer after ART [state 8]). D, Proportion who have died (a composite of 
died prior to ART [state 4] and died after ART [state 9]). Abbreviations: ART, antiretroviral therapy; LTFU, lost to follow-up.
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Current retention strategies generally treat LTFU as a uni-
form entity [32], but our results indicate that understanding the 
mechanisms of LTFU is essential for improving their effective-
ness. We found that patients who become LTFU prior to ART 
initiation are much less likely to reengage in care or transfer 
compared to those who become LTFU after initiating ART. We 
posit that these differences are likely driven by the underlying 
mechanisms associated with becoming LTFU at different time 
points (ie, early in care prior to starting ART vs after engaging 
in care long enough to be initiated on ART), rather than simply 
being an effect of initiating ART. Previous work on patient-
reported reasons for LTFU—including latent class analyses that 
identified unique LTFU phenotypes—support this hypothesis 
that barriers to care and care seeking behaviors vary across 
different stages of treatment [33–37]. Thus, future retention 
interventions should attempt to leverage patients’ treatment 
histories in order to more effectively target different mechan-
isms of LTFU.
Beyond the initial treatment period, our study also identified 
important downstream treatment gaps in the HIV care cascade. 
We found that only 61.8% of patients remained continuously 
retained after ART initiation over the first year, whereas an ad-
ditional 13.4% were in care only after reengaging after LTFU 
or transferring to a new clinic. Patients frequently churn in 
and out of care over time [2–8], but these transitions are often 
also associated with prolonged lapses in treatment [4]. Thus, 
they represent unique opportunities to intervene in patients 
who have already demonstrated they are at risk for poor en-
gagement. For example, Medecins Sans Frontieres’ “Welcome 
Back” program proactively facilitates care for returning patients 
in order to strengthen engagement and mitigate patient fears 
of poor treatment after their care lapse [36–38]. Streamlining 
the process of transferring between facilities could also help to 
minimize associated treatment lapses [32]. Finally, differenti-
ated service delivery can reduce the burden of accessing care 
for the majority of patients who remain stable while also re-
ducing patient volumes and allowing resources to be more fo-
cused on those who need it most [32]. Thus, understanding the 
heterogeneity in patients’ treatment histories over time can help 
treatment programs develop more comprehensive care delivery 
packages and move beyond 1-size-fits-all approaches.
Novel longitudinal methods such as multistate analyses rep-
resent a promising but underutilized tool for monitoring and 
evaluation as they can capture the dynamic nature of outcomes 
along HIV care cascade over time [5–8]. Patients’ treatment 
journeys do not linearly progress through the care cascade 1 
step at time. Rather, patients commonly transition back and 
forth between multiple care states over time, and these methods 
allow us to better quantify outcomes in relation to multiple 
interlinked cares states such as ART initiation, retention in care, 
LTFU, and reengagement over time. These methods are gaining 
traction [5–8, 11–13], but their use should be extended to other 
outcomes that commonly fluctuate over time, both in HIV (eg, 
viral load monitoring [suppressed vs unsuppressed or up to date 
vs not up to date], or pre-exposure prophylaxis persistence) as 
well as noncommunicable diseases (eg, medication and control 
status for hypertension or diabetes). Compared to more typical 
approaches (eg, cross-sectional analyses or survival analyses fo-
cused on single outcomes), these methods provide a better and 
more comprehensive approach to measuring patient outcomes 
along care cascades over time.
There are several limitations to this study. First, we were less suc-
cessful in tracing younger patients and patients from Lusaka, al-
though we attempted to minimize any bias from this by accounting 
for differences in tracing success in our sampling weights. Second, 
we were unable to follow patients after they had transferred to a dif-
ferent facility. Thus, we could not capture care transitions that oc-
curred after transfer, although previous work has documented delays 
in ART reinitiation among those transferring without official doc-
umentation [4]. Third, treatment standards have changed (ie, im-
plementation of universal treatment) since our data were collected 
in 2015 [14]. Nevertheless, our cohort represents patients who were 
eligible for ART at the time of linkage, and it is likely that the general 
patterns we observed (except for the rapidity of ART initiation) will 
still be relevant in the current era. Fourth, we had a limited duration 
of follow-up, precluding assessments of longer-term outcomes such 
as what happens after patients reengage in care after LTFU. Finally, 
we were unable to assess virologic outcomes as viral loads were not 
routinely collected in Zambia during our study period, although re-
sults from the ZAMPHIA survey suggest that just under 90% of pa-
tients in care and on ART will be virally suppressed [39].
In conclusion, we used multistate analytic methods to fully 
characterize longitudinal outcomes along the HIV care cas-
cade among people eligible for ART newly linking to care in 
Zambia. We found that 75.2% of patients overall were in care 
and on ART at 1 year, but only 61.8% had remained consist-
ently retained. Despite being ART-eligible, 43.5% of all mor-
tality occurred in patients prior to even initiating ART with 
failure to initiate ART primarily being driven by early lapses in 
care. Finally, we found that the likelihood of returning to care 
after LTFU differed depending on whether LTFU occurred 
prior to versus after ART initiation. Multistate approaches 
help to reveal the distinct care gaps at distinct time points 
that ultimately limit sustained treatment success, highlighting 
the importance of examining HIV care cascade outcomes in 
a manner that accounts for care transitions that occur over 
the course of a patient’s treatment history. Future efforts must 
now focus on learning how to best implement comprehensive 
packages of care that effectively target the varied care chal-
lenges patients may face over the course of lifelong treatment.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases on-
line. Consisting of data provided by the authors to benefit the reader, 
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